0001654954-20-007469.txt : 20200708 0001654954-20-007469.hdr.sgml : 20200708 20200708161638 ACCESSION NUMBER: 0001654954-20-007469 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200706 ITEM INFORMATION: Other Events FILED AS OF DATE: 20200708 DATE AS OF CHANGE: 20200708 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ChromaDex Corp. CENTRAL INDEX KEY: 0001386570 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 262940963 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37752 FILM NUMBER: 201018554 BUSINESS ADDRESS: STREET 1: 10900 WILSHIRE BLVD STREET 2: SUITE 600 CITY: LOS ANGELES STATE: CA ZIP: 90024 BUSINESS PHONE: 310-388-6706 MAIL ADDRESS: STREET 1: 10900 WILSHIRE BLVD STREET 2: SUITE 600 CITY: LOS ANGELES STATE: CA ZIP: 90024 FORMER COMPANY: FORMER CONFORMED NAME: CODY RESOURCES, INC. DATE OF NAME CHANGE: 20070112 8-K 1 cdxc8k_jul062020.htm CURRENT REPORT cdxc8k_jul062020
 

UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 
WASHINGTON, D.C. 20549
____________
 
FORM 8-K
 
CURRENT REPORT
 
     PURSUANT TO SECTION 13 OR 15(d) OF THE
 
SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported): July 6, 2020
 
CHROMADEX CORPORATION
 (Exact name of registrant as specified in its charter)
 
Delaware
001-37752
26-2940963
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
 
10900 Wilshire Blvd. Suite 600, Los Angeles, California 90024
(Address of principal executive offices, including zip code)
 
(310) 388-6706
 (Registrant's telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
CDXC
The Nasdaq Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
 

 
 
Item 8.01 Other Events.
 
ChromaDex Corporation (the “Company” or ChromaDex) recently became aware that, due to an administrative error, certain of the Company’s previously filed Annual Reports on Form 10-K, including the Annual Report on Form 10-K for the year ended December 31, 2019, as amended, contained the wrong filing, issued and/or expiration dates with respect to certain of the Company’s owned and licensed patents. The following table sets forth the Company’s existing owned and licensed patents with such filing, issued and/or expiration dates as corrected:
 
Patent Number
Title
Filing Date
Issued Date
Expires
Licensor
7,205,284
Potent immunostimulants from microalgae
7/10/2001
4/17/2007
3/9/2022
Licensed from University of Mississippi
7,776,326
Methods and compositions for treating neuropathies
6/3/2005
8/17/2010
6/24/2026
Licensed from Washington University
7,846,452
Potent immunostimulatory extracts from microalgae
7/28/2005
12/7/2010
7/28/2025
Licensed from University of Mississippi
8,106,184
Nicotinyl Riboside Compositions and Methods of Use
11/17/2006
1/31/2012
9/20/2027
Licensed from Cornell University
8,114,626
Yeast strain and method for using the same to produce Nicotinamide Riboside
3/26/2009
2/14/2012
1/5/2026
Licensed from Dartmouth College
8,133,917
Pterostilbene as an agonist for the peroxisome proliferator-activated receptor alpha isoform
10/25/2010
3/13/2012
8/18/2025
Licensed from the University of Mississippi and U.S. Department of Agriculture
8,197,807
Nicotinamide Riboside Kinase compositions and Methods for using the same
4/20/2006
6/12/2012
11/19/2026
Licensed from Dartmouth College
8,252,845
Pterostilbene as an agonist for the peroxisome proliferator-activated receptor alpha isoform
2/1/2012
8/28/2012
8/18/2025
Licensed from the University of Mississippi and U.S. Department of Agriculture
8,318,807
Pterostilbene Caffeine Co-Crystal Forms
7/30/2010
11/27/2012
7/21/2031
Licensed from Laurus Labs Private Limited
8,383,086
Nicotinamide Riboside Kinase compositions and Methods for using the same
4/12/2012
2/26/2013
4/20/2026
Licensed from Dartmouth College
8,399,712
Pterostilbene cocrystals
7/30/2010
3/19/2013
8/10/2031
Licensed from Laurus Labs Private Limited
8,524,782
Key intermediate for the preparation of Stilbenes, solid forms of Pterostilbene, and methods for making the same
1/21/2011
9/3/2013
2/1/2030
Licensed from Laurus Labs Private Limited
8,809,400
Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration
8/8/2011
8/19/2014
10/2/2028
Licensed from the University of Mississippi and U.S. Department of Agriculture
8,841,350
Method for treating non-melanoma skin cancer by inducing UDP-Glucuronosyltransferase activity using pterostilbene
5/8/2012
9/23/2014
5/8/2032
Co-owned by ChromaDex and University of California
8,889,126
Methods and compositions for treating neuropathies
5/28/2010
11/18/2014
6/3/2025
Licensed from Washington University
9,000,147
Nicotyl riboside compositions and methods of use
1/17/2012
4/7/2015
11/17/2026
Licensed from Cornell University
9,028,887
Method improve spatial memory via pterostilbene administration
5/22/2014
5/12/2015
6/10/2028
Licensed from the University of Mississippi and U.S. Department of Agriculture
9,295,688
Methods and compositions for treating neuropathies
10/10/2014
3/29/2016
6/3/2025
Licensed from Washington University
9,321,797
Nicotyl riboside compositions and methods of use
11/17/2014
4/26/2016
11/17/2026
Licensed from Cornell University
9,439,875
Anxiolytic effect of pterostilbene
5/11/2011
9/13/2016
12/11/2031
Licensed from the University of Mississippi and U.S. Department of Agriculture
9,975,915
Crystalline forms of nicotinoyl ribosides, modified derivatives thereof, and phosphorylated analogs thereof, and methods of preparation thereof
11/10/2017
5/22/2018
11/10/2037
Co-owned by ChromaDex and The Queen’s University of Belfast
10,000,519 
Methods of Preparing Nicotinamide Riboside and Derivatives Thereof 
7/24/2014 
6/19/2018 
7/24/2034 
Licensed from The Queen’s University of Belfast 
10,000,520
B-vitamin and amino acid conjugates ofnicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof
3/16/2017
6/19/2018
3/16/2037
Co-owned by ChromaDex and The Queen’s University of Belfast
10,183,036 
Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as NAD+ increasing precursors 
4/20/2017 
1/22/2019 
4/20/2037 
Owned by ChromaDex 
10,280,190 
Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof to enhance skin permeation in treating skin conditions 
3/16/2016 
5/7/2019 
5/31/2036 
Co-owned by ChromaDex and The Queen’s University of Belfast 
10,688,118 
Nicotinamide riboside compositions for topical use in treating skin conditions 
10/30/2014 
6/23/2020 
4/6/2035 
Owned by ChromaDex 
10,689,411 
Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof 
11/10/2017 
6/23/2020 
11/10/2037 
Co-owned by ChromaDex and The Queen’s University of Belfast 
  
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
 
 
 
 
 
 
 
CHROMADEX CORPORATION
 
 
 
Dated: July 8, 2020
 
 
 
 
 
 
 
 
 
 
 
 
By:
 
/s/ Kevin M. Farr                                                       
 
 
 
 
 
 
Name: Kevin M. Farr
 
 
 
 
 
 
Chief Financial Officer